GLOW is the Wolverine pairing, BPC-157 plus TB-500, with GHK-Cu stacked on top, a three-peptide regenerative blend in a single 70 mg vial. The draw is that each component pulls a different repair lever: GHK-Cu touches thousands of repair-related genes, TB-500 upregulates thymosin beta-4 systemically, and BPC-157 drives angiogenesis locally. No human RCT has tested the blend itself, and the guide says so plainly.
- GHK-Cu has been linked to shifts in more than 4,000 repair-related genes, which is why this blend reads regenerative rather than merely anti-inflammatory.Peptide Guide p.41
- TB-500 upregulates thymosin beta-4 for systemic repair while BPC-157 drives angiogenesis locally via VEGF: two different repair routes in one vial.Peptide Guide p.41-42
- In July 2026 the Pharmacy Compounding Advisory Committee recommended BPC-157 and TB-500 for the 503A bulks list, 8-6 each. The vote is advisory and non-binding, and BPC-157 remains an FDA Category 2 bulk substance with restricted compounding.Peptide Guide p.42
- Stated limits, not buried: no human RCT has tested the blend itself, and TB-500 has no published human efficacy trials.Peptide Guide p.42
- Copper sets the ceiling on extended work and it oxidizes with no visible color change, so serum copper and ceruloplasmin are the markers researchers track.Peptide Guide p.42